8th Nov 2019 07:00
8 November 2019
Diurnal Group plc
("Diurnal" or the "Company")
Vesting of LTIP awards
Diurnal Group plc (AIM: DNL), the specialty pharmaceutical company targeting patient needs in chronic endocrine (hormonal) diseases, announces that the Remuneration Committee has determined the proportion of options over ordinary shares of 5 pence each in Diurnal previously granted under the Diurnal Group plc Long Term Incentive Plan (the "Plan") to Directors of the Company that are exercisable at the vesting date of 8 November 2019:
Maximum number of potential shares to be issued under the Plan | Date of grant | Options vesting on 8 November 2019 | |
Martin Whitaker | 133,333 | 8 November 2016 | 80,000 |
Richard Bungay | 404,762 | 8 May 2017 | 242,857 |
The awards were granted under award agreements that incorporated the terms of the Plan and comprised a mix of tax-favoured 'EMI' awards and non-tax favoured awards. Further details of the awards were announced on 9 November 2016 and 8 May 2017.
The vested options remain subject to exercise. The exercise price payable per share under award is 5 pence per ordinary share. The awards are exercisable until 8 November 2026.
For further information, please visit www.diurnal.co.uk or contact: | |
Diurnal Group plc | +44 (0)20 3727 1000 |
Martin Whitaker, Chief Executive Officer | |
Richard Bungay, Chief Financial Officer | |
Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker) | +44 (0) 20 7886 2500 |
Corporate Finance: Freddy Crossley, Emma Earl | |
Corporate Broking: James Stearns | |
Cantor Fitzgerald Europe (Joint Broker) | +44 (0)20 7894 7000 |
Corporate Finance: Phil Davies, Will Goode, Michael Boot | |
Healthcare Equity Sales: Andrew Keith | |
FTI Consulting (Media and Investor Relations) | +44 (0)20 3727 1000 |
Simon Conway | |
Victoria Foster Mitchell | |
Notes to Editors
About Diurnal Group plc
Founded in 2004, Diurnal is a UK-based specialty pharma company developing high quality products for the global market for the life-long treatment of chronic endocrine conditions, including Congenital Adrenal Hyperplasia and Adrenal Insufficiency. Its expertise and innovative research activities focus on circadian-based endocrinology to yield novel product candidates in the rare and chronic endocrine disease arena.
For further information about Diurnal, please visit www.diurnal.co.uk
Related Shares:
DNL.L